Cargando…

Lot quality assurance sampling to assess coverage and compliance following mass drug administration to eliminate lymphatic filariasis in Fiji: A methodological approach

BACKGROUND: Assessing the quality of mass drug administration (MDA) rounds is a key component of lymphatic filariasis (LF) elimination programs. Routine collection of administrative coverage is unreliable, especially when pockets with low program coverage exist. To address this gap, we used lot qual...

Descripción completa

Detalles Bibliográficos
Autores principales: Rinamalo, Milika, Pezzoli, Lorenzo, Kama, Mike, Rafai, Eric, Kubuabola, Ilisapeci, Salusalu, Mosese, Kim, Sung Hye
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7500667/
https://www.ncbi.nlm.nih.gov/pubmed/32946536
http://dx.doi.org/10.1371/journal.pone.0238622
_version_ 1783583900484763648
author Rinamalo, Milika
Pezzoli, Lorenzo
Kama, Mike
Rafai, Eric
Kubuabola, Ilisapeci
Salusalu, Mosese
Kim, Sung Hye
author_facet Rinamalo, Milika
Pezzoli, Lorenzo
Kama, Mike
Rafai, Eric
Kubuabola, Ilisapeci
Salusalu, Mosese
Kim, Sung Hye
author_sort Rinamalo, Milika
collection PubMed
description BACKGROUND: Assessing the quality of mass drug administration (MDA) rounds is a key component of lymphatic filariasis (LF) elimination programs. Routine collection of administrative coverage is unreliable, especially when pockets with low program coverage exist. To address this gap, we used lot quality assurance sampling (LQAS) following the 10th annual LF-MDA round in Fiji to explore whether there was any area in which target coverage was not reached. We also assessed the level of drug compliance and satisfaction with the LF-MDA implementation strategy. METHODOLOGY/PRINCIPAL FINDINGS: We conducted a cross-sectional household survey in 3 divisions of Fiji. For LQAS, we defined 19 lots in 7 medical areas of the Suva sub-division and another 12 sub-divisions in the Central, Northern, and Eastern Divisions. A sample of 16 randomly selected household members was taken un each lot. We defined our decision rule as follows: if more than 1 person in a given lot did not swallow the medication, coverage was considered inadequate, i.e. less than 80%. Of the 7 lots in Suva sub-division and 12 lots in the 3 divisions, five and two lots, respectively, were identified as having inadequate coverage. The overall program coverage estimated from 304 samples was 92%, which was higher than the reported administrative coverage of 82%. About 98% of interviewees were offered the medication and 96% swallowed it. Non-participation arose from insufficient information on how to obtain the drugs. At least 92% were satisfied with the LF-MDA implementation strategy. CONCLUSIONS: Areas of low program coverage with results discordant with the reported administrative coverage existed in both urban and rural settings. Drug compliance and satisfaction were high, even after repeated rounds. We recommend increasing efforts to deliver the service in those areas with inadequate program coverage, as well as conducting timely coverage assessment through LQAS for corrective action.
format Online
Article
Text
id pubmed-7500667
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-75006672020-09-24 Lot quality assurance sampling to assess coverage and compliance following mass drug administration to eliminate lymphatic filariasis in Fiji: A methodological approach Rinamalo, Milika Pezzoli, Lorenzo Kama, Mike Rafai, Eric Kubuabola, Ilisapeci Salusalu, Mosese Kim, Sung Hye PLoS One Research Article BACKGROUND: Assessing the quality of mass drug administration (MDA) rounds is a key component of lymphatic filariasis (LF) elimination programs. Routine collection of administrative coverage is unreliable, especially when pockets with low program coverage exist. To address this gap, we used lot quality assurance sampling (LQAS) following the 10th annual LF-MDA round in Fiji to explore whether there was any area in which target coverage was not reached. We also assessed the level of drug compliance and satisfaction with the LF-MDA implementation strategy. METHODOLOGY/PRINCIPAL FINDINGS: We conducted a cross-sectional household survey in 3 divisions of Fiji. For LQAS, we defined 19 lots in 7 medical areas of the Suva sub-division and another 12 sub-divisions in the Central, Northern, and Eastern Divisions. A sample of 16 randomly selected household members was taken un each lot. We defined our decision rule as follows: if more than 1 person in a given lot did not swallow the medication, coverage was considered inadequate, i.e. less than 80%. Of the 7 lots in Suva sub-division and 12 lots in the 3 divisions, five and two lots, respectively, were identified as having inadequate coverage. The overall program coverage estimated from 304 samples was 92%, which was higher than the reported administrative coverage of 82%. About 98% of interviewees were offered the medication and 96% swallowed it. Non-participation arose from insufficient information on how to obtain the drugs. At least 92% were satisfied with the LF-MDA implementation strategy. CONCLUSIONS: Areas of low program coverage with results discordant with the reported administrative coverage existed in both urban and rural settings. Drug compliance and satisfaction were high, even after repeated rounds. We recommend increasing efforts to deliver the service in those areas with inadequate program coverage, as well as conducting timely coverage assessment through LQAS for corrective action. Public Library of Science 2020-09-18 /pmc/articles/PMC7500667/ /pubmed/32946536 http://dx.doi.org/10.1371/journal.pone.0238622 Text en © 2020 Rinamalo et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Rinamalo, Milika
Pezzoli, Lorenzo
Kama, Mike
Rafai, Eric
Kubuabola, Ilisapeci
Salusalu, Mosese
Kim, Sung Hye
Lot quality assurance sampling to assess coverage and compliance following mass drug administration to eliminate lymphatic filariasis in Fiji: A methodological approach
title Lot quality assurance sampling to assess coverage and compliance following mass drug administration to eliminate lymphatic filariasis in Fiji: A methodological approach
title_full Lot quality assurance sampling to assess coverage and compliance following mass drug administration to eliminate lymphatic filariasis in Fiji: A methodological approach
title_fullStr Lot quality assurance sampling to assess coverage and compliance following mass drug administration to eliminate lymphatic filariasis in Fiji: A methodological approach
title_full_unstemmed Lot quality assurance sampling to assess coverage and compliance following mass drug administration to eliminate lymphatic filariasis in Fiji: A methodological approach
title_short Lot quality assurance sampling to assess coverage and compliance following mass drug administration to eliminate lymphatic filariasis in Fiji: A methodological approach
title_sort lot quality assurance sampling to assess coverage and compliance following mass drug administration to eliminate lymphatic filariasis in fiji: a methodological approach
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7500667/
https://www.ncbi.nlm.nih.gov/pubmed/32946536
http://dx.doi.org/10.1371/journal.pone.0238622
work_keys_str_mv AT rinamalomilika lotqualityassurancesamplingtoassesscoverageandcompliancefollowingmassdrugadministrationtoeliminatelymphaticfilariasisinfijiamethodologicalapproach
AT pezzolilorenzo lotqualityassurancesamplingtoassesscoverageandcompliancefollowingmassdrugadministrationtoeliminatelymphaticfilariasisinfijiamethodologicalapproach
AT kamamike lotqualityassurancesamplingtoassesscoverageandcompliancefollowingmassdrugadministrationtoeliminatelymphaticfilariasisinfijiamethodologicalapproach
AT rafaieric lotqualityassurancesamplingtoassesscoverageandcompliancefollowingmassdrugadministrationtoeliminatelymphaticfilariasisinfijiamethodologicalapproach
AT kubuabolailisapeci lotqualityassurancesamplingtoassesscoverageandcompliancefollowingmassdrugadministrationtoeliminatelymphaticfilariasisinfijiamethodologicalapproach
AT salusalumosese lotqualityassurancesamplingtoassesscoverageandcompliancefollowingmassdrugadministrationtoeliminatelymphaticfilariasisinfijiamethodologicalapproach
AT kimsunghye lotqualityassurancesamplingtoassesscoverageandcompliancefollowingmassdrugadministrationtoeliminatelymphaticfilariasisinfijiamethodologicalapproach